Author details

Full Name

John D Lambris

Affiliation

ORCID

Career Start Year

1979

Papers

515

H Index

108

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36980228	Terminal Complement Activation Is Induced by Factors Released from Endplate Tissue of Disc Degeneration Patients and Stimulates Expression of Catabolic Enzymes in Annulus Fibrosus Cells.		2023
36328123	Complement-regulatory biomaterial coatings: Activity and selectivity profile of the factor H-binding peptide 5C6.		2023
37670180	A guide to complement biology, pathology and therapeutic opportunity.		2023
37081885	evaluation of iron oxide nanoparticle-induced thromboinflammatory response using a combined human whole blood and endothelial cell model.		2023
36755352	Complement-targeted therapeutics: An emerging field enabled by academic drug discovery.		2023
37306457	The Complement-Targeted Inhibitor Mini-FH Protects against Experimental Periodontitis via Both C3-Dependent and C3-Independent Mechanisms.		2023
35090732	Compstatins: the dawn of clinical C3-targeted complement inhibition.	Trends in Pharmacological Sciences	2022
35839748	The future of neuroimmunology research for CNS disease therapeutics.	Trends in Pharmacological Sciences	2022
36028293	Complement Is Required for Microbe-Driven Induction of Th17 and Periodontitis.	Journal of Immunology	2022
35760703	Complement component C3: A structural perspective and potential therapeutic implications.	Seminars in Immunology	2022
35691883	C3-targeted host-modulation approaches to oral inflammatory conditions.	Seminars in Immunology	2022
35570131	Application of the C3 inhibitor compstatin in a human whole blood model designed for complement research - 20 years of experience and future perspectives.	Seminars in Immunology	2022
36127336	Insight into mode-of-action and structural determinants of the compstatin family of clinical complement inhibitors.	Nature Communications	2022
35788185	Considering innate immune responses in SARS-CoV-2 infection and COVID-19.	Nat Rev Immunol	2022
35787973	Emerging opportunities for C3 inhibition in the eye.	Seminars in Immunology	2022
35853795	Complement C3 activation in the ICU: Disease and therapy as Bonnie and Clyde.	Seminars in Immunology	2022
35720304	Snake Venom Inflammation Induced in Human Whole Blood: Role of the Complement System.	Frontiers in Immunology	2022
35977025	Complement C3 inhibition in severe COVID-19 using compstatin AMY-101.	Science advances	2022
35915008	Recent developments in C3-targeted complement therapeutics.	Seminars in Immunology	2022
34971753	Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis.	Cancer Lett	2022
34526511	C3 complement inhibition prevents antibody-mediated rejection and prolongs renal allograft survival in sensitized non-human primates.	Nature Communications	2021
34231390	Erythrocytes identify complement activation in patients with COVID-19.	Am J Physiol Lung Cell Mol Physiol	2021
33945504	Is complement the culprit behind COVID-19 vaccine-related adverse reactions?	Journal of Clinical Investigation	2021
33521674	Efficacy matters: broadening complement inhibition in COVID-19.	Lancet Rheumatology, The	2021
34145258	Serum amyloid P component is an essential element of resistance against Aspergillus fumigatus.	Nature Communications	2021
33936074	C5a-C5aR1 Axis Activation Drives Envenomation Immunopathology by the Snake .	Frontiers in Immunology	2021
34189574	Complement mediates binding and procoagulant effects of ultralarge HIT immune complexes.	Blood	2021
33174372	CD14 inhibition improves survival and attenuates thrombo-inflammation and cardiopulmonary dysfunction in a baboon model of Escherichia coli sepsis.	Journal of Thrombosis and Haemostasis	2021
33115645	Response to "Comment on Mastellos and colleagues and efficacy of complement-targeting drugs in COVID-19".	Clinical Immunology	2021
33321207	Targeting complement components C3 and C5 for the retina: Key concepts and lingering questions.	Progress in Retinal and Eye Research	2021
34732467	Air Bubbles Activate Complement and Trigger Hemostasis and C3-Dependent Cytokine Release Ex Vivo in Human Whole Blood.	Journal of Immunology	2021
34618684	Phase IIa clinical trial of complement C3 inhibitor AMY-101 in adults with periodontal inflammation.	Journal of Clinical Investigation	2021
34505065	Complement activation promoted by the lectin pathway mediates C3aR-dependent sarcoma progression and immunosuppression.	Nature Cancer	2021
31171642	Complement C3 inhibition by compstatin Cp40 prevents intra- and extravascular hemolysis of red blood cells.	Haematologica	2020
32360516	The first case of COVID-19 treated with the complement C3 inhibitor AMY-101.	Clinical Immunology	2020
32229292	Prolonged intraocular residence and retinal tissue distribution of a fourth-generation compstatin-based C3 inhibitor in non-human primates.	Clinical Immunology	2020
32327719	Complement as a target in COVID-19?	Nature Reviews Immunology	2020
33543018	Interaction of with extracellular matrix components resulting in immunomodulation and bacterial eradication.	Matrix Biology Plus	2020
32759504	Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis.	Journal of Clinical Investigation	2020
32533108	Author Correction: Complement as a target in COVID-19?	Nature Reviews Immunology	2020
32983160	Thirty-Eight-Negative Kinase 1 Is a Mediator of Acute Kidney Injury in Experimental and Clinical Traumatic Hemorrhagic Shock.	Frontiers in Immunology	2020
32815311	Complement modulation reverses pathology in Y402H-retinal pigment epithelium cell model of age-related macular degeneration by restoring lysosomal function.	Stem Cells Transl Med	2020
32961333	Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy.	Clinical Immunology	2020
32909942	Soluble collectin-12 mediates C3-independent docking of properdin that activates the alternative pathway of complement.	eLife	2020
32844416	Current understanding of periodontal disease pathogenesis and targets for host-modulation therapy.	Periodontology 2000	2020
31045344	Interlaboratory Comparison of Hydrogen-Deuterium Exchange Mass Spectrometry Measurements of the Fab Fragment of NISTmAb.	Anal Chem	2019
31998311	Editorial: Therapeutic Modulation of the Complement System: Clinical Indications and Emerging Drug Leads.	Frontiers in Immunology	2019
31819218	Therapeutic targeting of the complement system.	Nature Reviews Drug Discovery	2019
31562490	'Stealth' corporate innovation: an emerging threat for therapeutic drug development.	Nat Immunol	2019
31605100	Author Correction: 'Stealth' corporate innovation: an emerging threat for therapeutic drug development.	Nat Immunol	2019